Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135057 | 1.00 | HRH3 (0.57) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL6135382 | 1.00 | HRH3 (0.57) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL20241810 | 0.89 | HRH3 (0.53) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL1714405 | 0.88 | HRH3 (0.74) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL1714712 | 0.82 | HRH3 (0.77) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL6135422 | 0.82 | SLC6A2 (0.60) | HRH1DRD3DRD2KCNH2HTR7 | |
| SCHEMBL4233204 | 0.81 | DRD2 (0.70) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL3206275 | 0.80 | CYP2D6 (0.58) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL7487458 | 0.80 | HRH3 (0.53) | HRH3HRH1DRD3DRD2KCNH2 | |
| SCHEMBL6132263 | 0.79 | CHRNA10 (0.43) | HRH3HRH1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | HRH3 1440/4885HRH1 1307/4885DRD3 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.